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ABSTRACT
Background. Erythropoiesis-stimulating agents (ESAs) with
intravenous iron supplementation are the main treatment for
anaemia in patients with chronic kidney disease. Although ob-
servational studies suggest better outcomes for patients who
achieve higher haemoglobin (Hb) levels, randomized con-
trolled trials comparing higher and lower Hb targets have led
to safety concerns over higher targets and to changes in treat-
ment guidelines.
Methods. Quarterly data from 2005 to 2013 were obtained on
28 936 haemodialysis patients from the UK Renal Registry. We
examined trends in ESA use and average dose, Hb and ferritin
values over time and Hb according to the UK Renal Association
guideline range.
Results. The average ESA dose declined over time, with sharper
decreases of epoetin seen towards the end of 2006 and from
2009. Average Hb for patients on ESAs was 114.1 g/L [95% con-
ﬁdence interval (CI) 113.7, 114.6] in the ﬁrst quarter of 2005,
which decreased to 109.6 g/L (95% CI 109.3, 109.9) by the
end of 2013. Average serum ferritin was 353 µg/L (95% CI
345, 360) at the start of 2005, increasing to 386 µg/L (95% CI
380, 392) in the ﬁnal quarter of 2013. The percentage of patients
with Hb in the range of 100–120 g/L increased from 46.1 at the
start of 2005 to 57.6 at the end of 2013.
Conclusions. Anaemia management patterns for haemodialy-
sis patients changed in the UK between 2005 and 2013. These
patterns most likely reﬂect clinician response to emerging trial
evidence and practice guidelines. Registries play an important
role in continued observation of anaemia management and
will monitor further changes as new evidence on optimal care
emerges.
Keywords: anaemia management, erythropoiesis-stimulating
agents, ESA, haemodialysis, haemoglobin
INTRODUCTION
Nearly 57 000 adult patients were receiving renal replacement
therapy (RRT) in the UK at the end of 2013 (prevalence 888/
million), and demand for RRT is rising [1]. Anaemia is a com-
mon complication for patients with chronic kidney disease
(CKD), resulting in reduced quality of life, fatigue, decreased
exercise capacity and shortness of breath. Erythropoiesis-
stimulating agents (ESAs) are the main treatment for CKD pa-
tients with anaemia [2] and are effective in correcting and
maintaining haemoglobin (Hb) levels and decreasing the
need for blood transfusions. Intravenous (IV) iron supplements
are an important adjunct in the treatment of anaemia in pa-
tients on haemodialysis.
Even partial treatment of anaemia with ESAs is expensive,
and full correction of Hb requires much higher doses than par-
tial correction. When ESAs were ﬁrst introduced into clinical
practice, randomized controlled trials (RCTs) were not per-
formed, as it was thought unnecessary and even unethical to
leave a control group with untreated anaemia. However, the© The Author 2016. Published by Oxford University Press
on behalf of ERA-EDTA. This is an Open Access article distributed under the
terms of theCreativeCommonsAttribution License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction
in any medium, provided the original work is properly cited.
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question of whether full correction of anaemia is preferable to
partial correction has now been tested in several RCTs. Besarab
et al. [3] randomized haemodialysis patients with cardiovascu-
lar comorbidity to full or partial correction of anaemia: this trial
was terminated early when it became clear that beneﬁt from full
correction was highly improbable. The US Food and Drug
Administration later classiﬁed the trial results as showing in-
creased risk of all-cause mortality for the group randomized
to the higher Hb target [4] and a later reanalysis of the full
trial report showed no improvement in quality of life [5].
Three large RCTs in patients with CKD not yet on dialysis
have been completed [6–8] and found no evidence of beneﬁts
of a higher (compared with lower) Hb target on cardiovascular
events or a composite outcome of death, myocardial infarction,
hospitalization for congestive heart failure and stroke, or they
found increased risk of adverse events. These conclusions are
difﬁcult to reconcile with data from numerous observational
studies that demonstrate the best outcomes are in patients
who have high Hb concentrations but require only low doses
of ESAs (130–140 g/L) [9–11]. One interpretation is that ESA-
sensitive patients derive survival beneﬁt from full correction of
anaemia, but that patients with ESA resistance (which is a pre-
dictor of poor survival) may be harmed by the high doses of
ESAs prescribed under the trial protocols in the (often unsuc-
cessful) attempt to normalize Hb concentration.
The target Hb for patients with CKD in the UK Renal As-
sociation Clinical Practice Guidelines (3rd edition, 2002–07)
was >100 g/L with no suggested maximum [12]. These were
altered to 105–125 g/L (4th edition, 2007–09) [13] and low-
ered to 100–120 g/L in the latest version (5th edition, 2010)
[2] following publication of the RCTs in 2006 [6, 8] and 2009
[7]. The impact of these guideline changes on ESA dosing
and hence on achieved Hb levels remains unclear. We, there-
fore, examined trends in ESA dosing in UK haemodialysis
patients between 2005 and 2013 and corresponding trends
in achieved Hb levels. We related these trends to changes
in the national guidelines for management of anaemia.
METHODS
We identiﬁed RCTs and treatment guidelines with the potential
to affect anaemia management for patients on haemodialysis
during the period 2005–13. These were used to construct a time-
line depicting when changes in management were expected.
The UKRenal Registry (UKRR) collects clinical and biochem-
ical data from all patients ≥18 years of age receiving RRT in the
UK. Data are extracted electronically, on a quarterly basis, and are
validated and cleaned prior to analysis [14]. Some centres submit
data extracts that include ESA doses. All patients who received
haemodialysis in 2005–13 in centres submitting ESA doses
were included in the analyses. Centres reporting fewer than
60% of haemodialysis patients being treated with ESAs were con-
sidered to have incomplete data and their data for that quarter
were excluded. Patients from 37 centres across England, Wales
and Northern Ireland were included in the analyses (from a
total of 62 centres in these regions). A patient was considered
to be incident during their ﬁrst year of haemodialysis.
Patients were deﬁned as being on an ESA if a drug type (dar-
bepoetin, epoetin-α, -β or not otherwise speciﬁed, or methoxy
polyethylene glycol-epoetin β) and/or a dose was recorded. ESA
dose is presented as the weekly epoetin dose in our analysis.
Doses of ≤150 IU/week (likely to be darbepoetin) were harmo-
nized with epoetin data by multiplying by 200. No adjustments
were made with respect to route or frequency of administration.
The measurement of Hb (g/L) that was closest to the end of the
quarter was extracted. Serum ferritin was measured in µg/L.
Data were also extracted on age, sex, race (White, South Asian,
Black, Chinese, other or missing), year of starting RRT and pri-
mary renal disease (diabetes, glomerulonephritis, hypertension,
polycystic kidneys, pyelonephritis, renal vascular disease, other
or uncertain [15]).
Statistical methods
For each calendar year, we derived descriptive statistics sum-
marizing the demographic and clinical characteristics of the co-
hort. ESA dose and ferritin were log transformed, as they had
positively skewed distributions. The percentage of patients on
the different ESA drug types were calculated for each quarter.
To examine trends in anaemia management over time, we cal-
culated the geometric mean of the ESA dose [with 95% conﬁ-
dence interval (CI)] per quarter, stratiﬁed by drug type [(i)
darbepoetin and (ii) epoetin-α, -β or not otherwise speciﬁed;
there were not enough numbers to also include amethoxy poly-
ethylene glycol-epoetin β group]. The doses were also examined
restricting to incident patients. The mean achieved Hb levels
were calculated separately for ESA-treated and non-treated pa-
tients.We calculated the proportion of all patients on ESA treat-
ment over time and the proportion of patients with Hb in the
categories <100, 100–120 and >120 g/L. Patients were also put
into categories according to their ESA status: those always re-
ceiving ESAs over the time period, patients changing on/off
ESAs over the time period and those never receiving ESAs.
Trends in these statistics over time were compared with the
timeline of events with the potential to affect anaemia manage-
ment. All means and proportions were standardized by year
using direct standardization according to the age, sex, race
and primary renal disease distribution for all years of data com-
bined. The numbers with missing values for these factors were
reported and people with missing values were excluded from
the analyses. All analyses were carried out using Stata version
13 (StataCorp, College Station, TX, USA).
RESULTS
Timeline of events that may have affected anaemia
management
Events that may have affected anaemia management in the
UK are summarized in Figure 1. The CHOIR trial, published in
2006 [8], randomized 1432 patients with CKD not on RRT to a
Hb target of 135 or 113 g/L. There was evidence of increased
risk of the primary outcome (a composite of death, myocardial
infarction and hospitalization for heart failure or stroke) in the
high-Hb compared with the low-Hb group [hazard ratio (HR)













2 K. Birnie et al.
 at U







in 2006 [6], 603 patients with CKD not on RRT were rando-
mized to a target Hb of 130–150 or 105–115 g/L. Early com-
plete correction of anaemia did not reduce the risk of
cardiovascular events. In the TREAT trial, which was the largest
RCT andwas published in 2009 [7], 4038 patients with diabetes,
CKD and anaemia were randomly assigned to achieve a Hb
level of ∼130 g/L with the use of darbepoetin alfa or placebo
(patients in the placebo group received darbepoetin alfa as a
rescue agent if Hb <90 g/L). The risk of a composite outcome
of death or cardiovascular event was similar in the two groups
[HR for darbepoetin alfa versus placebo 1.05 (95% CI 0.94,
1.17)], but there was a higher incidence of stroke in the darbe-
poetin alfa arm [HR 1.92 (95% CI 1.38, 2.68)]. Following pub-
lication of these RCTs, the target Hb for patients with CKDwas
lowered to 100–120 g/L in UK Renal Association and National
Institute for Health and Care Excellence (NICE) treatment
guidelines [2, 16]. The Kidney Disease: Improving Global Out-
comes (KDIGO) 2012 guidelines suggest that ESA therapy
should be started when Hb is between 90 and 100 g/L for adult
dialysis patients and that ESAs should not be used tomaintain an
Hb concentration >115 g/L in adult patients with CKD, but that
individualization of therapy will be necessary as some patients
may have improvements in quality of life at an Hb concentration
>115 g/L and will be prepared to accept the risks [17].
Characteristics of the study cohort
A total of 28 936 haemodialysis patients were included in the
cohort. A total of 1659 patients (5.9%) never received ESAs
within the study period (2005–13), 6648 (23.0%) changed on/
off ESAs over the time period and 20 593 (71.2%) always re-
ceived ESA therapy. Darbepoetin was the drug used most fre-
quently (51.3%), followed by epoetin-β (21.8%), epoetin-α
(17.3%), epoetin not otherwise speciﬁed (7.4%) and methoxy
polyethylene glycol-epoetin β (2.3%). Demographic character-
istics of the yearly cohorts are shown in Table 1. The number of
patients included in the cohort almost doubled over time, but
the age, sex and race distributions changed very little. In
2013, the median age of patients was 66.9 years (interquartile
range 54.1–76.8), with 7726 (61.3%) male and 10 095 (80.7%)
of White race. The proportion of patients with diabetes as the
primary renal disease increased over time, from 17.4% of
patients in 2005 to 21.8% in 2013. The number of incident
patients included increased steadily over time from N = 1423
in 2005 to N = 2193 in 2013.
Use of ESAs, 2005–13
Prior to 2007, when existing guidelines had no upper limit to
Hb levels, the geometric mean dose of ESA remained stable for
epoetin drugs and showed a steady increase for darbepoetin
(Figure 2), while the proportion of patients on ESAs remained
relatively constant (Figure 3). Near the end of 2006 and in early
2007, there appears to be a decline in the proportion of patients
on ESAs, with a modest dose reduction, most likely in response
to the joint publication of the NICE guideline [18] and the
CHOIR and CREATE trials [4, 6] (see Figure 1). The decline
in patients treated with ESAs continues until 2013 [percentage
of patients receiving ESAs decreases from 92.8 (95% CI 92.0,
93.5) in the ﬁrst quarter of 2005 to 87.1 (95% CI 86.5, 87.8)
in the ﬁnal quarter of 2013]. There is an overall decline in aver-
age darbepoetin dose from mid-2006. Average doses of epoetin
drugs declined from 2006, followed by a rise in 2008–09, fol-
lowed by a second decline from around 2010 after the publica-
tion of the TREAT trial [7] and further published guidelines.
The average darbepoetin dose declined from 6431 IU/week
(95% CI 6221, 6649) in the ﬁrst quarter of 2005 to 5921 IU/
week (95% CI 5780, 6066) in the last quarter of 2013. The aver-
age epoetin dose declined from 8107 IU/week (95% CI 7884,
8336) in the ﬁrst quarter of 2005 to 7310 IU/week (95% CI
7133, 7491) in the last quarter of 2013. The percentage of
patients on the different ESA drug types is shown in the online
supplement (Supplementary data, Figure S1). Similar ESA dose
patterns were observed in incident patients (Supplementary
data, Figure S2).
Achieved Hb and ferritin, 2005–13
The Hb patterns for patients on ESAs mirror what is seen
with ESA dosage, so that we observed an initial small increase
in mean Hb until the end of 2006 followed by a steady decline
(Figure 4). The mean Hb for patients on ESA in the ﬁrst quarter
of 2005 was 114.1 g/L (95% CI 113.7, 114.6) and was 109.6 g/L
(95% CI 109.3, 109.9) by the end of 2013. The decline in mean
Hb appears to start in 2007, following NICE guidelines [18] and
the publication of the CHOIR [8] and CREATE [6] trials in
2006. The decrease in average Hb levels is then observed for
many years—when further guidelines and the TREAT trial
[7] were published—until a settling of Hb levels in 2012 and
2013. The lowering inHbwas seen for patients whowere receiv-
ing ESAs, those not on treatment and across treatment groups
(always on ESAs, changing on/off ESAs, never on ESAs;
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Figure 5), although the numbers of patients never receiving ESAs
were small and the pattern showed large ﬂuctuations. The per-
centage of patients with Hb >120 g/L has decreased over time,
from 36.3 at the start of 2005 to 22.4 at the end of 2013 (Figure 6).
The percentage of patients with Hb in the range of 100–120 g/L
has increased from 46.1 at the start of 2005 to 57.6 at the end of
2013. From the second quarter of 2011 onwards, >55% of
haemodialysis patients have had Hb levels in the range of 100–
120 g/L. In contrast to average Hb levels, there has been a sharp
increase in ferritin levels from 2008 to 2011 (Figure 7), with a de-
cline near the beginning of 2011, after which levels appear to have
stabilized. The average serum ferritin was 353 µg/L (95% CI 345,
360) in the ﬁrst quarter of 2005 and 386 µg/L (95% CI 380, 392)
in the ﬁnal quarter of 2013.
DISCUSSION
Summary of ﬁndings
We examined ESA doses and Hb levels in haemodialysis
patients from 2005 to 2013 in the UK. This period included
the publication of major clinical trials and changes to treatment
practice guidelines. The use of ESAs has decreased over time, but
it is not possible to determine which events had the most inﬂu-
ence on dosing, as results from RCTs and anaemia management
guidelines were also published during this time. The average Hb
level decreased over time, with levels after 2011 largely compliant
with theUKRenal Association 2010 target range of 100–120 g/L.
F IGURE 2 : Geometric mean ESA weekly dose and 95% CI. The
dashed vertical lines indicate the publication of the CHOIR and
CREATE RCTs (2006) and TREAT (2009).
F IGURE 3 : Percentage use of ESAs with 95% CIs, in all haemodi-
alysis patients. The dashed vertical lines indicate the publication of the
CHOIR and CREATE RCTs (2006) and TREAT (2009).
Table 1. Characteristics of the cohort by year
2005 2006 2007 2008 2009 2010 2011 2012 2013
Number of patients
Incident 1423 1645 1703 1840 1895 1870 1842 1960 2193
Total (including incident) 6930 7896 8637 9419 10 326 10 648 10 824 11 462 12 609
Age, years, median (IQR) 65.5 (51.5–75.0) 66.0 (52.1–75.4) 65.9 (52.4–75.5) 66.1 (52.9–75.7) 66.4 (53.2–75.9) 66.7 (53.7–76.2) 66.8 (53.5–76.5) 67.0 (53.9–76.6) 66.9 (54.1–76.8)
Sex, n (%)
Male 4216 (60.8) 4880 (61.8) 5346 (61.9) 5784 (61.4) 6262 (60.6) 6471 (60.8) 6579 (60.8) 7037 (61.4) 7726 (61.3)
Female 2714 (39.2) 3016 (38.2) 3291 (38.1) 3635 (38.6) 4064 (39.4) 4177 (39.2) 4245 (39.2) 4425 (38.6) 4883 (38.7)
Race, n (%)
White 5477 (83.6) 6286 (84.1) 6884 (83.4) 7580 (83.4) 8419 (83.2) 8783 (83.2) 8822 (81.9) 9489 (82.9) 10 095 (80.7)
Black 295 (4.5) 328 (4.4) 367 (4.5) 400 (4.4) 467 (4.6) 457 (4.3) 514 (4.8) 499 (4.4) 779 (6.2)
South Asian 677 (10.3) 751 (10.1) 882 (10.7) 983 (10.8) 1073 (10.6) 1143 (10.8) 1263 (11.7) 1266 (11.1) 1403 (11.2)
Chinese 39 (0.6) 41 (0.6) 46 (0.6) 45 (0.5) 50 (0.5) 55 (0.5) 51 (0.5) 49 (0.4) 68 (0.5)
Other 64 (1.0) 70 (0.9) 75 (0.9) 81 (0.9) 105 (1.0) 125 (1.2) 128 (1.2) 138 (1.2) 160 (1.3)
Missing 378 420 383 330 212 85 46 21 104
Primary renal disease, n (%)
Diabetes 1182 (17.4) 1400 (18.0) 1581 (18.6) 1792 (19.4) 2004 (19.7) 2065 (19.6) 2191 (20.4) 2351 (20.7) 2718 (21.8)
Glomerulonephritis 1027 (15.1) 1184 (15.2) 1287 (15.2) 1389 (15.0) 1509 (14.8) 1565 (14.9) 1577 (14.7) 1700 (15.0) 1875 (15.1)
Hypertension 386 (5.7) 400 (5.2) 458 (5.4) 510 (5.5) 599 (5.9) 637 (6.1) 642 (6.0) 747 (6.6) 864 (6.9)
Polycystic kidneys 491 (7.2) 565 (7.3) 605 (7.1) 656 (7.1) 704 (6.9) 732 (7.0) 702 (6.5) 772 (6.8) 827 (6.6)
Pyelonephritis 725 (10.6) 814 (10.5) 948 (11.2) 992 (10.7) 1056 (10.4) 1035 (9.8) 1024 (9.6) 1046 (9.2) 1141 (9.2)
Renal vascular disease 561 (8.2) 640 (8.2) 678 (8.0) 702 (7.6) 736 (7.2) 780 (7.4) 769 (7.2) 801 (7.1) 767 (6.2)
Other 965 (14.2) 1113 (14.3) 1184 (13.9) 1345 (14.5) 1485 (14.6) 1598 (15.2) 1667 (15.5) 1776 (15.6) 1955 (15.7)
Uncertain 1477 (21.7) 1652 (21.3) 1751 (20.6) 1865 (20.2) 2079 (20.4) 2115 (20.1) 2156 (20.1) 2167 (19.1) 2314 (18.6)
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A decrease in Hb levels over time was observed for both patients
who were treated with ESAs and those not receiving ESAs, sug-
gesting that after the reduction in the Hb target thresholds,
patients were started on ESAs at lower levels of Hb. A small,
but sharp increase in ferritin levels was seen from 2008 to
2011, coinciding with decreases in ESA use. This pattern cannot
be directly explained by adherence to revised anaemia manage-
ment guidelines. Serum ferritin is a marker of iron balance, i.
e. iron loss from occult bleeding, blood sampling and loss of
blood in the dialysis machine, versus dietary absorption plus
IV supplementation. The observed pattern of ferritin may have
been driven by coincident economic pressures to improve the
cost-effectiveness of ESA use as well as by emerging evidence
that IV iron was safe and effective [19]. Alternatively, it could
be that clinicians are administrating the same amount of iron
to patients, but it is not being used up so quickly because of
reduced ESA doses. Interestingly, the last 2 years have seen a
stable pattern with no increase or decrease in levels.
Comparison with other studies
Results from RCTs and clinical practice patterns in the USA
have inﬂuenced anaemia management in recent years. A study
of US non-dialysis chronic kidney disease patients found that
the emergence of safety concerns following RCTs and the sub-
sequent changes in product labelling, restrictions to reimburse-
ment for ESAs and changes to clinical practice guidelines all
appeared to inﬂuence physician dosing practices, resulting in
less frequent use of ESAs, lower ESA doses and lower achieved
Hb levels [20]. A study of US haemodialysis patients from the
United States Renal Data System found that ESA dosing de-
creased from 2007 and that Hb levels mirrored ESA dosing
trends [21]. The Dialysis Outcomes and Practice Patterns
Study (DOPPS) Practice Monitor was developed to detect
and report on trends in dialysis care before, during and after
implementation of the End-Stage Renal Disease Prospective
Payment System, which was initiated by the US Centers for
F IGURE 5 : MeanHb levels over time in all haemodialysis patients by
ESA status. Crosses represent patients always receiving ESAs; triangles
represent patients changing on/off ESAs over the time period; circles
represent patients never receiving ESAs. The dashed vertical lines in-
dicate the publication of the CHOIR and CREATE RCTs (2006) and
TREAT (2009).
F IGURE 4 : Mean Hb levels over time with 95% CIs in all haemo-
dialysis patients. Circles represent patients not receiving ESAs; trian-
gles represent patients receiving ESAs. The dashed vertical lines
indicate the publication of the CHOIR and CREATE RCTs (2006) and
TREAT (2009).
F IGURE 6 : Percentages in the Hb groups (<100, 100–120 and
>120 g/L) in all haemodialysis patients. Dark grey represents Hb
<100 g/L, mid-grey represents Hb 100–120 g/L and light grey
represents Hb >120 g/L.
FIGURE 7: Geometric mean ferritin with 95% CI in all haemodialysis
patients. The dashed vertical lines indicate the publication of the
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Medicare and Medicaid Services in January 2011. The percent-
age of patients with Hb >120 g/L declined from 32 in August
2010 to 14 in December 2012. The mean prescribed dose of pa-
tients receiving IV epoetin decreased from 20 500 U/week in
August 2010 to 13 300 U/week in December 2012, with the
greatest decline occurring during June–August 2011. An in-
crease of iron use was observed in 2011 and serum measures
of iron stores increased [22]. However, the increase in average
IV iron dose did not persist beyond 2011. The sustained in-
crease in ferritin levels in US dialysis patients after policy
changes in 2011 appeared to be partly due to reductions in
ESA dosing and not solely IV iron dosing practices [23]. In
Germany, dialysis procedure rates were changed in 2002 from
per-session to weekly ﬂat rate payments, and quality assurance
was introduced in 2009 with deﬁned treatment targets for dif-
ferent indices including Hb. DOPPS phases 1–4 (1998–2011)
found that Hb levels increased starting in 1998 and remained
consistent through 2005, with only 8–10% of patients below
100 g/L. Around 90% of patients were prescribed ESAs, with
the dose declining since peaking in 2006. IV iron use was high-
est in 2011 [24].
Strengths and weaknesses
The UK Renal Registry is a large and highly representative
database allowing trends in clinical practice patterns to be cap-
tured [11]. This study gives an indication that clinicians are re-
sponding to changes in guidelines important for patient safety.
The analysis of ESA usage is, however, limited by incomplete
data returns, as some renal centres do not routinely record com-
puterized data on ESA dose or drug type. Centres reporting
<60% of haemodialysis patients being treated with ESAs were
considered to have incomplete data and were excluded from
the analysis. These exclusion criteria are relatively arbitrary,
but they are based in part on the frequency distribution graph
of the centres’ ESA use as it appears in the data. The percentage
of patients on ESAs is calculated from these data and incom-
plete data returns risk impacting on any conclusions drawn.
The dose conversion used for darbepoetin may not accurately
estimate weekly epoetin dose. There is no information on
how much iron therapy was being used to treat anaemia in
this population; however, data were available on ferritin levels,
giving an indication of achieved iron stores over the period.
Data were only obtained from haemodialysis patients and are
not generalizable to peritoneal dialysis patients or other CKD
populations.
CONCLUSIONS
Anaemiamanagement patterns for haemodialysis patients have
changed in the UK between 2005 and 2013, with these changes
likely to have been in response to results from RCTs and chan-
ging clinical practice guidelines. There has been a decrease in
ESA use, dose and average achieved Hb levels in recent years,
with fewer patients having Hb levels >120 g/L and more pa-
tients having Hb levels within the 100–120 g/L target range.
Average serum ferritin levels have increased in the same time
period. Previous research suggests that clinicians are responsive
to clinical guidelines, though the degree to which new practices
are adopted can vary considerably depending on the context
[25, 26]. It is likely that in this case, economic considerations
due to the price of ESAs further facilitated adoption of the
guidelines, as clinicians could reduce unit expenditure by redu-
cing ESA dosage and treating fewer patients. The continued
monitoring of anaemia management through registry data is
important for patient safety and enhancing patient quality
of life and enables us to ensure that any new evidence on the
optimal use of ESA therapy for haemodialysis patients is
translated into everyday clinical care.
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